Cargando…
Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure
The envelope of Human Immunodeficiency Virus type 1 (HIV-1) consists of a liquid-ordered membrane enriched in raft lipids and containing the viral glycoproteins. Previous studies demonstrated that changes in viral membrane lipid composition affecting membrane structure or curvature can impair infect...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131562/ https://www.ncbi.nlm.nih.gov/pubmed/30233582 http://dx.doi.org/10.3389/fimmu.2018.01983 |
_version_ | 1783354132500840448 |
---|---|
author | Nieto-Garai, Jon Ander Glass, Bärbel Bunn, Carmen Giese, Matthias Jennings, Gary Brankatschk, Beate Agarwal, Sameer Börner, Kathleen Contreras, F. Xabier Knölker, Hans-Joachim Zankl, Claudia Simons, Kai Schroeder, Cornelia Lorizate, Maier Kräusslich, Hans-Georg |
author_facet | Nieto-Garai, Jon Ander Glass, Bärbel Bunn, Carmen Giese, Matthias Jennings, Gary Brankatschk, Beate Agarwal, Sameer Börner, Kathleen Contreras, F. Xabier Knölker, Hans-Joachim Zankl, Claudia Simons, Kai Schroeder, Cornelia Lorizate, Maier Kräusslich, Hans-Georg |
author_sort | Nieto-Garai, Jon Ander |
collection | PubMed |
description | The envelope of Human Immunodeficiency Virus type 1 (HIV-1) consists of a liquid-ordered membrane enriched in raft lipids and containing the viral glycoproteins. Previous studies demonstrated that changes in viral membrane lipid composition affecting membrane structure or curvature can impair infectivity. Here, we describe novel antiviral compounds that were identified by screening compound libraries based on raft lipid-like scaffolds. Three distinct molecular structures were chosen for mode-of-action studies, a sterol derivative (J391B), a sphingosine derivative (J582C) and a long aliphatic chain derivative (IBS70). All three target the viral membrane and inhibit virus infectivity at the stage of fusion without perturbing virus stability or affecting virion-associated envelope glycoproteins. Their effect did not depend on the expressed envelope glycoproteins or a specific entry route, being equally strong in HIV pseudotypes carrying VSV-G or MLV-Env glycoproteins. Labeling with laurdan, a reporter of membrane order, revealed different membrane structure alterations upon compound treatment of HIV-1, which correlated with loss of infectivity. J582C and IBS70 decreased membrane order in distinctive ways, whereas J391B increased membrane order. The compounds' effects on membrane order were reproduced in liposomes generated from extracted HIV lipids and thus independent both of virion proteins and of membrane leaflet asymmetry. Remarkably, increase of membrane order by J391B required phosphatidylserine, a lipid enriched in the HIV envelope. Counterintuitively, mixtures of two compounds with opposite effects on membrane order, J582C and J391B, did not neutralize each other but synergistically inhibited HIV infection. Thus, altering membrane order, which can occur by different mechanisms, constitutes a novel antiviral mode of action that may be of general relevance for enveloped viruses and difficult to overcome by resistance development. |
format | Online Article Text |
id | pubmed-6131562 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61315622018-09-19 Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure Nieto-Garai, Jon Ander Glass, Bärbel Bunn, Carmen Giese, Matthias Jennings, Gary Brankatschk, Beate Agarwal, Sameer Börner, Kathleen Contreras, F. Xabier Knölker, Hans-Joachim Zankl, Claudia Simons, Kai Schroeder, Cornelia Lorizate, Maier Kräusslich, Hans-Georg Front Immunol Immunology The envelope of Human Immunodeficiency Virus type 1 (HIV-1) consists of a liquid-ordered membrane enriched in raft lipids and containing the viral glycoproteins. Previous studies demonstrated that changes in viral membrane lipid composition affecting membrane structure or curvature can impair infectivity. Here, we describe novel antiviral compounds that were identified by screening compound libraries based on raft lipid-like scaffolds. Three distinct molecular structures were chosen for mode-of-action studies, a sterol derivative (J391B), a sphingosine derivative (J582C) and a long aliphatic chain derivative (IBS70). All three target the viral membrane and inhibit virus infectivity at the stage of fusion without perturbing virus stability or affecting virion-associated envelope glycoproteins. Their effect did not depend on the expressed envelope glycoproteins or a specific entry route, being equally strong in HIV pseudotypes carrying VSV-G or MLV-Env glycoproteins. Labeling with laurdan, a reporter of membrane order, revealed different membrane structure alterations upon compound treatment of HIV-1, which correlated with loss of infectivity. J582C and IBS70 decreased membrane order in distinctive ways, whereas J391B increased membrane order. The compounds' effects on membrane order were reproduced in liposomes generated from extracted HIV lipids and thus independent both of virion proteins and of membrane leaflet asymmetry. Remarkably, increase of membrane order by J391B required phosphatidylserine, a lipid enriched in the HIV envelope. Counterintuitively, mixtures of two compounds with opposite effects on membrane order, J582C and J391B, did not neutralize each other but synergistically inhibited HIV infection. Thus, altering membrane order, which can occur by different mechanisms, constitutes a novel antiviral mode of action that may be of general relevance for enveloped viruses and difficult to overcome by resistance development. Frontiers Media S.A. 2018-09-04 /pmc/articles/PMC6131562/ /pubmed/30233582 http://dx.doi.org/10.3389/fimmu.2018.01983 Text en Copyright © 2018 Nieto-Garai, Glass, Bunn, Giese, Jennings, Brankatschk, Agarwal, Börner, Contreras, Knölker, Zankl, Simons, Schroeder, Lorizate and Kräusslich. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Nieto-Garai, Jon Ander Glass, Bärbel Bunn, Carmen Giese, Matthias Jennings, Gary Brankatschk, Beate Agarwal, Sameer Börner, Kathleen Contreras, F. Xabier Knölker, Hans-Joachim Zankl, Claudia Simons, Kai Schroeder, Cornelia Lorizate, Maier Kräusslich, Hans-Georg Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure |
title | Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure |
title_full | Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure |
title_fullStr | Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure |
title_full_unstemmed | Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure |
title_short | Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure |
title_sort | lipidomimetic compounds act as hiv-1 entry inhibitors by altering viral membrane structure |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131562/ https://www.ncbi.nlm.nih.gov/pubmed/30233582 http://dx.doi.org/10.3389/fimmu.2018.01983 |
work_keys_str_mv | AT nietogaraijonander lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure AT glassbarbel lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure AT bunncarmen lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure AT giesematthias lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure AT jenningsgary lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure AT brankatschkbeate lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure AT agarwalsameer lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure AT bornerkathleen lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure AT contrerasfxabier lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure AT knolkerhansjoachim lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure AT zanklclaudia lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure AT simonskai lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure AT schroedercornelia lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure AT lorizatemaier lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure AT krausslichhansgeorg lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure |